{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-318069","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2026-07-27T20:08:03+00:00","discovered_at":"2026-07-27T20:09:00.289218+00:00","generated_at":"2026-07-27T20:09:15.011429+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M","bullets":["Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.","Net loss $8.4M ($0.01/share) vs $148.4M ($0.19/share) in Q2 2025.","Diagnostics revenue $74.5M (down from $101.1M due to oncology asset sale to Labcorp); pharma product revenue $42.9M.","Cash and equivalents $314.4M; $105.3M of stock repurchased under $200M program.","FY 2026 total revenue guidance $560-585M; Q3 2026 revenue guidance $131-142M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-318069","json":"https://secwatch.observer/filing/0001193125-26-318069.json","markdown":"https://secwatch.observer/filing/0001193125-26-318069.md","text":"https://secwatch.observer/filing/0001193125-26-318069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/0001193125-26-318069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/opk-20260727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T20:09:15.011429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}